Literature DB >> 25034289

Molecular pathogenesis of cholangiocarcinoma.

Sumera Rizvi1, Gregory J Gores.   

Abstract

It has become increasingly apparent of late that inflammation plays an integral role in a spectrum of malignancies including cholangiocarcinoma (CCA). Primary sclerosing cholangitis with chronic inflammation is the most common risk factor for CCA in the Western world. Recent work has highlighted that inflammatory pathways are essential in carcinogenesis and tissue invasion and migration. Inflammation advances carcinogenesis by induction of DNA damage, evasion of apoptosis, promotion of cell proliferation, and neoangiogenesis. CCA is characterized by the presence of a desmoplastic stroma consisting of cancer-associated fibroblasts, tumor-associated macrophages, and tumor-infiltrating lymphocytes. This rich inflammatory milieu is vital to the cancer ecosystem, and targeting its components represents an attractive therapeutic option.

Entities:  

Mesh:

Year:  2014        PMID: 25034289      PMCID: PMC4137891          DOI: 10.1159/000360502

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  43 in total

1.  Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.

Authors:  Jung-Hwan Yoon; Hajime Higuchi; Nathan W Werneburg; Scott H Kaufmann; Gregory J Gores
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

Review 2.  Genetic profiling of intrahepatic cholangiocarcinoma.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

3.  Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis.

Authors:  Norihisa Ishimura; Steven F Bronk; Gregory J Gores
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

4.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Authors:  Daniela Sia; Yujin Hoshida; Augusto Villanueva; Sasan Roayaie; Joana Ferrer; Barbara Tabak; Judit Peix; Manel Sole; Victoria Tovar; Clara Alsinet; Helena Cornella; Brandy Klotzle; Jian-Bing Fan; Christian Cotsoglou; Swan N Thung; Josep Fuster; Samuel Waxman; Juan Carlos Garcia-Valdecasas; Jordi Bruix; Myron E Schwartz; Rameen Beroukhim; Vincenzo Mazzaferro; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-04       Impact factor: 22.682

5.  IDH1 and IDH2: not your typical oncogenes.

Authors:  Zachary J Reitman; D Williams Parsons; Hai Yan
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

6.  Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome.

Authors:  Jennifer J Hofmann; Ann C Zovein; Huilin Koh; Freddy Radtke; Gerry Weinmaster; M Luisa Iruela-Arispe
Journal:  Development       Date:  2010-12       Impact factor: 6.868

7.  IL-6 involvement in epithelial cancers.

Authors:  Zachary T Schafer; Joan S Brugge
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 8.  Classification, diagnosis, and management of cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-13       Impact factor: 11.382

9.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

10.  Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Authors:  Fang Wang; Jeremy Travins; Byron DeLaBarre; Virginie Penard-Lacronique; Stefanie Schalm; Erica Hansen; Kimberly Straley; Andrew Kernytsky; Wei Liu; Camelia Gliser; Hua Yang; Stefan Gross; Erin Artin; Veronique Saada; Elena Mylonas; Cyril Quivoron; Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Shunqi Yan; Stuart Murray; Wentao Wei; Yi Gao; Lenny Dang; Marion Dorsch; Sam Agresta; David P Schenkein; Scott A Biller; Shinsan M Su; Stephane de Botton; Katharine E Yen
Journal:  Science       Date:  2013-04-04       Impact factor: 63.714

View more
  11 in total

1.  Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.

Authors:  Runping Liu; Xiaojiaoyang Li; Xiaoyan Qiang; Lan Luo; Phillip B Hylemon; Zhenzhou Jiang; Luyong Zhang; Huiping Zhou
Journal:  J Biol Chem       Date:  2015-10-30       Impact factor: 5.157

2.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

3.  Capsaicin Enhances the Drug Sensitivity of Cholangiocarcinoma through the Inhibition of Chemotherapeutic-Induced Autophagy.

Authors:  Zai-Fa Hong; Wen-Xiu Zhao; Zhen-Yu Yin; Cheng-Rong Xie; Ya-Ping Xu; Xiao-Qin Chi; Sheng Zhang; Xiao-Min Wang
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

4.  Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans.

Authors:  L Che; B Fan; M G Pilo; Z Xu; Y Liu; A Cigliano; A Cossu; G Palmieri; R M Pascale; A Porcu; G Vidili; M Serra; F Dombrowski; S Ribback; D F Calvisi; X Chen
Journal:  Oncogenesis       Date:  2016-12-05       Impact factor: 7.485

5.  Bioactive constituents isolated from Atractylodes lancea (Thunb.) DC. rhizome exhibit synergistic effect against cholangiocarcinoma cell.

Authors:  Pongsakorn Martviset; Wanna Chaijaroenkul; Phunuch Muhamad; Kesara Na-Bangchang
Journal:  J Exp Pharmacol       Date:  2018-10-25

Review 6.  Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies.

Authors:  Stefania Cannito; Chiara Milani; Andrea Cappon; Maurizio Parola; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

7.  Tumor Lymphatic Interactions Induce CXCR2-CXCL5 Axis and Alter Cellular Metabolism and Lymphangiogenic Pathways to Promote Cholangiocarcinoma.

Authors:  Sukanya Roy; Subhashree Kumaravel; Priyanka Banerjee; Tori K White; April O'Brien; Catherine Seelig; Rahul Chauhan; Burcin Ekser; Kayla J Bayless; Gianfranco Alpini; Shannon S Glaser; Sanjukta Chakraborty
Journal:  Cells       Date:  2021-11-09       Impact factor: 7.666

8.  MC-LR-induced interaction between M2 macrophage and biliary epithelial cell promotes biliary epithelial cell proliferation and migration through regulating STAT3.

Authors:  Minghao Yan; Shen Gu; Chun Pan; Yabing Chen; Xiaodong Han
Journal:  Cell Biol Toxicol       Date:  2021-01-21       Impact factor: 6.691

9.  Podoplanin is an important stromal prognostic marker in perihilar cholangiocarcinoma.

Authors:  Halmurat Obulkasim; Xiaolei Shi; Jun Wang; Jun Li; Bo Dai; Pengwen Wu; Shuai Wang; Xun Wang; Yitao Ding
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

10.  miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma.

Authors:  Dechao Jiao; Yan Yan; Shaofeng Shui; Gang Wu; JianZhuang Ren; Yanli Wang; Xinwei Han
Journal:  Oncotarget       Date:  2017-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.